EUVIMEDEUVIMED entdecken
Crossref

Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis

Antonio M Caballero-Mateos, Teresa Valdés-Delgado, Raúl Olmedo-Martín, Patricia Romero-Cara, María del Mar Martín-Rodríguez, Ana Lancho Muñoz, Melody Moreno-Barrueco, Raúl Gijón-Villanova, Nuria Fernández-Moreno, Francisco J Rodríguez-González, Álvaro Hernández-Martínez, Ana María Trapero-Martínez und 5 weitere

World Journal of Gastroenterology · 14.11.2026 · 32 (42)

DOI: 10.3748/wjg.119693 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 14.11.2026. Verfasst von Antonio M Caballero-Mateos und 16 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Many patients with Crohn’s disease (CD) remain uncontrolled despite multiple biologic therapies. Risankizumab, a selective interleukin-23p19 inhibitor, has shown efficacy in clinical trials, but real-world data in multirefractory CD are still scarce. AIM To evaluate the 12-month effectiveness and safety of risankizumab in a real-world cohort of patients with moderate-to-severe CD treated across multiple centers in Andalusia, Spain. METHODS Multicenter ambispective real-world study including adults with CD treated with risankizumab across 12 Andalusian hospitals (AIRIS-Crohn registry). Effectiveness outcomes were clinical remission (Harvey-Bradshaw index < 5), steroid-free remission (SFR), biochemical remission, and endoscopic response/remission at week 12, 6 months and 12 months. Modified non-responder imputation was applied to discontinuations. RESULTS Among 205 patients with highly refractory CD (median 2 prior failed advanced therapies; 81% prior ustekinumab exposure; 61% extraintestinal manifestations; 39% prior intestinal surgery), risankizumab rapidly improved clinical activity and maintained stable remission rates over 12 months. Clinical remission improved from 20% at baseline to 49% at week 12, 46% at 6 months and 49% at 12 months (P < 0.05 for all). SFR was maintained in 41%-44% throughout follow-up. Perianal disease response was observed in 65% at week 12 and 80% at 6 months. Endoscopic remission was achieved in 32% at 6 months. Treatment persistence exceeded 90% at one year. In multivariable analysis, prior vedolizumab exposure was related to lower odds of SFR (odds ratio = 0.41; 95% confidence interval: 0.17-0.99). Risankizumab demonstrated a reassuring safety profile: Only 3.4% of patients discontinued due to adverse events, and no serious infections, opportunistic infections, malignancies, or deaths occurred during follow-up. CONCLUSION In one of the largest real-world cohorts of multirefractory CD, risankizumab delivered rapid and sustained clinical benefit, meaningful SFR, robust treatment persistence, and a reassuring safety profile. These findings strengthen the role of interleukin-23 blockade as a key therapeutic strategy for patients with limited treatment options in everyday practice.

Zitieren

APA

Caballero-Mateos, A. M., Valdés-Delgado, T., Olmedo-Martín, R., Romero-Cara, P., Martín-Rodríguez, M. D. M., Muñoz, A. L., Moreno-Barrueco, M., Gijón-Villanova, R., Fernández-Moreno, N., Rodríguez-González, F. J., Hernández-Martínez, Á., Trapero-Martínez, A. M., Bejarano-García, A., Cantero, J. M. B., Mata-Perdigón, F. J., Sáez-Díaz, A., & Argüelles-Arias, F. (2026). Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis. World Journal of Gastroenterology, 32(42). https://doi.org/10.3748/wjg.119693

Vancouver

Caballero-Mateos AM, Valdés-Delgado T, Olmedo-Martín R, Romero-Cara P, Martín-Rodríguez MDM, Muñoz AL, et al. Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis. World Journal of Gastroenterology. 2026;32(42). doi:10.3748/wjg.119693

BibTeX
@article{CaballeroMateos2026,
  author = {Caballero-Mateos, Antonio M and Valdés-Delgado, Teresa and Olmedo-Martín, Raúl and Romero-Cara, Patricia and Martín-Rodríguez, María del Mar and Muñoz, Ana Lancho and Moreno-Barrueco, Melody and Gijón-Villanova, Raúl and Fernández-Moreno, Nuria and Rodríguez-González, Francisco J and Hernández-Martínez, Álvaro and Trapero-Martínez, Ana María and Bejarano-García, Ana and Cantero, José Manuel Benitez and Mata-Perdigón, Francisco J and Sáez-Díaz, Antonia and Argüelles-Arias, Federico},
  title = {Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis},
  journal = {World Journal of Gastroenterology},
  year = {2026},
  volume = {32},
  number = {42},
  doi = {10.3748/wjg.119693}
}
Kostenlos starten →